Enhancement of Cancer Chemotherapeutic Efficacy via Bone-Targeted Drug Delivery Carrier in Bone Metastases

Xinghe Xue1–4
Jiachen Yu1–4
Fengfeng Lu1–4
Hongyi Jiang1–4
Xiangyang Wang1–3

1Department of Orthopaedic, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, People's Republic of China; 2The Second School of Medicine, Wenzhou Medical University, Wenzhou, 325027, Zhejiang, People's Republic of China; 3Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou, 325027, Zhejiang, People's Republic of China; 4Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325011, Zhejiang, People's Republic of China

Purpose: Bone metastases are common in malignant tumors, especially for the advanced cancers. Chemotherapy is an important treatment in clinic, but the application is limited due to the severe adverse reactions. We try to design bone-targeted drug delivery systems (DDS) for the delivery of chemotherapeutic drugs in bone metastatic carcinoma.

Material and Methods: We added alendronate (Aln) to metal organic framework (MOF) to synthesize a new bone-targeted DDS named Aln-MOF. Doxorubicin (DOX) as a classic anti-cancer drug was encapsulated. The material characterization, drug release and bone affinity were detected. In vitro experiment, the cell toxicity was detected by cck-8 test and cellular uptake were detected by laser scanning confocal microscope and flow cytometry. In vivo experiment, the pharmacokinetics of DDS in the blood was analyzed by fluorescence spectrophotometer and the biodistribution was detected by a multi-mode optical in vivo imaging system. The anti-tumor effects of MOFDOX and Aln-MOFDOX were evaluated by monitoring the tumor volume and weight during the animal experiment. In addition, the toxicity of DDS to different organs was determined by HE staining.

Results: Aln-MOF showed good stability, no cytotoxicity and better bone affinity than MOF. Both MOFDOX and Aln-MOFDOX could release DOX, and the release rate at pH = 5.5 was faster than the rate at pH = 7.4. The cellular uptake of Aln-MOF and MOF showed no difference. Aln-MOF had a long retention time in blood, which is beneficial for the enrichment of Aln-MOF in tumor sites. Aln-MOF mainly concentrated at bone metastases in mice. MOFDOX and Aln-MOFDOX could effectively delay tumor progression, and the effect of Aln-MOFDOX was more obvious (P < 0.05).

Conclusion: Our study confirmed that Aln-MOF has good stability, bone targeting and biosafety. Aln-MOFDOX could release DOX and effectively kill tumor cells of bone metastases. Aln-MOFDOX has a promising prospect in the treatment of bone metastasis.

Keywords: tumor, metal organic framework, alendronate, doxorubicin

Introduction

Bone metastases, which are common in malignant tumors, will cause physical and psychological damage to patients and seriously affect their normal life. Bone metastases mainly occur in advanced stage of tumors such as lung cancer, breast cancer and prostate cancer. The metastatic rate is 40–85% and the metastatic rate of prostate cancer is the highest which is up to 85%.1,2 In addition to the above solid tumors, bone metastases can occur in 95% of multiple myeloma, which is a malignant plasma cell disease.3
The pathogenesis of bone metastases is still unclear. The tumor cells of primary malignant tumors (lung cancer, breast cancer, prostate cancer, etc.) migrate from their primary lesion to the circulatory system, mainly blood circulation. The tumor cells will metastasize to bone tissue and form bone metastases by the effect of different bone chemokines, such as connective tissue growth factor (CTGF), osteopontin (OPN) and IL-11 and so on. What’s more, the surface molecules of bone endovascular skin also play an important role in the process of bone metastases formation. The tumor cells often enter dormant state when they concentrate at bone tissue which can last years or even decades. Once the tumor cells are activated, they will rapidly proliferate and destroy bone tissue, causing a series of clinical symptoms. Lytic bone metastasis, which is the most serious type, will lead to skeletal related events (SREs), such as neoplastic pain, pathological fracture, tumor-derived hypercalcemia and spinal cord nerve compression. The mechanism of dormancy and activation is still unclear.

Chemotherapy is an important means to treat primary tumors and bone metastases, such as doxorubicin (DOX). As systemic application of chemotherapy drugs, it will cause severe adverse reactions for the lack of tumor targeting ability. In order to reduce the adverse reactions of chemotherapy drugs, some special materials can be selected as drug delivery systems (DDS). We can modify bone-targeting molecules to these DDS to provide bone-targeting properties. As a result, these new DDS are chosen to serve as drug delivery carriers to deliver chemotherapy drugs to bone metastases. At present, bisphosphonates especially alendronate (Aln) are the most widely used for bone targeting. Aln has a high affinity to hydroxyapatite in bone tissue. Aln can modify a variety of materials to provide bone targeting property, which has been confirmed in many studies.

These DDS must have good biocompatibility and drug loading capacity. According to the structure and composition of DDS, they can be divided into organic DDS and inorganic DDS. The organic DDS have good biocompatibility and biodegradability, while inorganic DDS are easily controllable in size, shape and functionalize. Metal organic framework (MOF) is formed by the polymerization of iron, zinc, calcium and other metals through the bonding of imidazoles, amines and phosphonates. Because of the special construction combining both inorganic matters and organic matters, MOF has advantages of both organic and inorganic DDS. MOF has high porosity, high surface area, good thermal and chemical stability, which lead to excellent drug loading capacity and drug leakage resistance. Recently, Tan et al synthesized a new multifunctional MOF-based nanohybrids which combined MOF with thermosensitive hydrogels. DOX and celecoxib were both loaded to treat localized oral cancer and the therapy efficacy and cell internalization were evaluated. This new nanocomposite showed unique biological abilities in terms of pH-responsiveness, antitumor efficacy and biocompatibility. MOF seems to be a promising DDS for cancer treatment.

In this study, we constructed a mouse model of breast cancer bone metastases. We modified MOF with Aln and compound a new bone-targeting DDS (Aln-MOF) to deliver chemotherapy drug to bone tissue. Our study consisted four parts: synthesis of MOF and Aln-MOF, material characterization testing, in vitro cell experiments and in vivo animal experiments. The purpose of our study was to confirm that Aln-MOF had good biological safety, stability and bone targeting. When DOX was encapsulated in Aln-MOF, it could effectively treat bone metastases and reduce the cytotoxicity of DOX to other normal organs.

Materials and Methods

Materials

Zinc nitrate hexahydrate, dimethylimidazole, methyl alcohol and DOX were obtained from baichuan Biotech company (China). Cy5 and Rhob were obtained from Liuhe Biotech company (China). Dulbecco’s Modified Eagle Medium (DMEM) was purchased from Huantai Inc. (Gibco, Grand Island, USA). 4’,6-Diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, St Louis, USA) and fluorescent aqueous mounting medium (Sigma-Aldrich, St Louis, USA) were obtained from Xinri Biotech company and used according to the manufacturer’s instructions. Fetal bovine serum (FBS, ExCell Bio, Shanghai, China) was purchased from Huihong Biotech company. Other reagents were purchased from Sangon and used as received.

Synthesis of MOF, Aln-MOF, MOF<sub>DOX</sub> and Aln-MOF<sub>DOX</sub>

Zeolitic imidazole framework (ZIF) is one type of MOF. ZIF-8 is a kind of topological nanoparticle formed by self-assembly of transition metal atoms with organic imidazole and its derivatives, which has good drug loading capacity.
and biocompatibility. We chose ZIF-8 as our delivery system.

We synthesize MOF according to previously reported studies with a little modification. Six hundred milligram zinc nitrate hexahydrate (Zn(NO$_3$)$_2$·6H$_2$O) and 1.3g dimethylimidazole were dissolved in two glass bottles containing 10mL methanol in each one. The mixture of two solutions was placed on a magnetic agitator and stirred for 30 minutes (37°C, 600 r·min$^{-1}$). Then we placed the stirred mixture in a centrifuge for 10 minutes (10,000 r·min$^{-1}$) and removed the supernatant to get the centrifuge product. After repeated washing, the reactants were dried overnight in a vacuum lyophilizer to remove the solvent and stored at room temperature for further experiments.

30.5mm (8.2g) Aln was dissolved in 50mL methanol. We combined 2mL Aln solution (1.22mM) with 100mg prepared MOF and placed on a magnetic agitator for 48 hours (37°C, 600 r·min$^{-1}$). The rest procedures were as same as the synthesis of MOF and we get Aln-MOF finally.

As the effective anti-tumor ability of DOX, we chose DOX as our chemotherapy drug. We encapsulated DOX in our prepared MOF and Aln-MOF. 12.5mM (6.8g) DOX was dissolved in 50mL methanol solution to prepare DOX solution for later use. We added 100mg prepared MOF or Aln-MOF to 2mL DOX solution (0.5mM DOX) and place the mixed solution on a magnetic stirrer for 48 hours (37°C, 600 r·min$^{-1}$). Then, the procedures of centrifugation, washing and freeze-drying were done as we mentioned above. Finally, we got MOF$_{DOX}$ and Aln-MOF$_{DOX}$ which encapsulated DOX.

**Morphological Detection**

Transmission Electron Microscope (TEM) was used to take pictures of Aln-MOF and MOF to observe the morphology of the nanoparticles. X-ray Diffraction (XRD) at 30 kV and 10 mA was used to do the phase analysis, including Aln-MOF, MOF and Aln. In addition, the chemical structures were analyzed by a Fourier transform infrared spectrometer (FTIR) with a wavenumber range of 500–4000 cm$^{-1}$. The surface composition and elemental valence were identified by X-ray photoelectron spectroscopy (XPS).

The prepared MOF 50mg and Aln-MOF 50mg were respectively dissolved in 10mL PBS with 10% FBS to prepare a solution of 5mg/mL. The prepared solution was placed in Zetasizer Nano ZEN3600 dynamic light scattering tester to detect the nanoparticle diameter of MOF and Aln-MOF. Then, at different time points (2, 4, 8, 24, 48, 72h), the average diameter of MOF and Aln-MOF was detected to analyze the stability.

**Detection of Drug Release Kinetics**

The prepared MOF$_{DOX}$ 50mg and Aln-MOF$_{DOX}$ 50mg were respectively dissolved in 10mL distilled water to prepare a solution of 5mg/mL. UV spectrophotometer was used to detect the concentration of DOX in the solution. The wavelength of 480 nm was selected and blank MOF particles were used as the basic correction. Then the drug load of the two particles was calculated by the formula below: LC =$ W_0/W_1$, $W_0$ was the amount of DOX in the particle, $W_1$ was the number of MOF or Aln-MOF particles.

The particles would meet two different pH values when entering into the body, the environment of blood (pH = 7.4) and intracellular lysosomal enzymes (pH = 5.5). Thirty-milliliter PBS with different pH values was added into the dialysis tube and the pH values were adjusted to 5.5 and 7.4, respectively. Twenty-milligram MOF$_{DOX}$ and Aln-MOF$_{DOX}$ was added into the dialysis tube, respectively. After stirring on a magnetic agitator (37°C, 100 r·min$^{-1}$), 1mL solution, containing 500μL MOF$_{DOX}$ or Aln-MOF$_{DOX}$ and 500μL PBS with different pH, was detected by microplate reader to calculate the concentration of DOX at different time point (0.5, 1, 2, 4, 6, 8, 12, 24, 48 h).

**Bone Affinity Test**

The bone affinity of the prepared Aln-MOF and MOF was detected by ultraviolet spectrophotometer. Three hundred microgram Aln-MOF and MOF were added into an EP tube containing 500μL distilled water (c$_0$=0.6μg/μL). The tibia of the mice was taken and added into the above solution. After the mixture was taken and added into the above solution. After the mixture was placed on a constant temperature shaker for 24 hours at room temperature for 24 hours, the particle concentration c$_1$ of the remaining liquid was detected by ultraviolet spectrophotometry. The bone affinity was calculated according to the formula:

\[ \text{BDA (BondBindingaffinity) } (\%) = \left( c_0 - c_1 / c_0 \right) \times 100\% . \]

**Mouse Breast Cancer 4T1 Cell Culture**

The Mouse breast cancer 4T1 cells were purchased from American type culture collection (ATCC). The 4T1 cells were inoculated in RRMI-1640 medium containing 10% FBS+1% dual antibodies, and then cultured in carbon
dioxide incubator (37 °C, 5% CO₂). The medium in the culture dish should be changed every other day, and the 4T1 cell was passaged every 3 days. We chose the second or third generation as our experimental subjects. All the experimental cells are in logarithmic growth.

Cck-8 Test
We need to detect the cytotoxicity of three groups of nanoparticles, namely Aln-MOF, MOF DOX and Aln-MOF DOX. According to the concentration of DOX drug, it was divided into 0.25, 0.5, 1.0, 2.0, 4.0 μg/mL groups from low to high (the drug loading of particle DOX was 0.65 μg/mg). Cck-8 test was used to detect the cytotoxicity.

Laser Scanning Confocal Microscopy
DAPI, Alexa Fluo 488 and RhoB were used to label the cell nucleus, cytoskeleton and nanoparticles of the 4T1 cells, respectively. Then, laser scanning confocal microscopy was used for imaging analysis. Finally, the fluorescence intensities of MOF and Aln-MOF were compared.

Flow Cytometric Analysis
RhoB was used to stain MOF and Aln-MOF particles. Then, flow cytometry was used to quantitatively analyze the cells uptaking RhoB-stained MOF and Aln-MOF. The difference of the cell number and fluorescence intensity of RhoB positive cells were counted to calculate the uptake of MOF and Aln-MOF by the 4T1 cells.

Animal Model
We selected Balb/c mice as our experimental animal, which were authorized by the Animal Protection and Utilization Committee of University of Chinese Academy of Sciences and provided by Vital River Laboratories (Beijing, China). All the parts involving animal experiment ethics in our study have been reported to the Animal Ethics Committee of University of Chinese Academy of Sciences for approval (WIUCAS21071205). All the animal experimental procedures were consistent with the national standard “Laboratory Animal-Guideline for Ethical Review of Animal Welfare” (GB/T35892-2018) of China.

The 4T1 cells were allocated into a certain proportion (cell concentration =10⁴/μL). 50 μL of the cell solution was injected into the bilateral tibia of Balb/c mice to establish the animal model of bone metastasis.

Duration of MOF and Aln-MOF in Blood
We used MOF and Aln-MOF particles to encapsulate Cy5 fluorescent molecules in the same way as DOX was encapsulated. We dissolve MOF Cy5 and Aln-MoF Cy5 in distilled water (5 mg/mL). Then we combine 360 μL MOF Cy5 or Aln-MoF Cy5 solution and add 40 μL 10X PBS to prepare isotonic liquid which was injected into mice through the caudal vein. At different time points (0.5, 1, 2, 4, 6, 8, 12, 24, 48h), 200 μL orbital blood was collected and centrifuged at 3000 rpm for 5 minutes to obtain the serum for detection. The concentration of MOF Cy5 or Aln-MoF Cy5 in serum at different time points was detected by fluorescence spectrophotometer.

Distribution of MOF and Aln-MOF
We used a multi-mode optical in vivo imaging system to detect the distribution of MOF and Aln-MOF in mice. After establishing mice with bone metastases for 2 weeks, we injected 400 μL isotonic solutions (360 μL of MOF Cy5 or Aln-MOF Cy5 solution +40 μL 10X PBS) into mice through the caudal vein. The distribution of MOF Cy5 or Aln-MOF Cy5 was detected by the multi-mode optical in vivo imaging system at different time points (0.5, 2, 6, 24h). At 24h, the mice were sacrificed and different organs were detected by the multi-mode optical in vivo imaging system.

The Therapeutic Effect of MOF DOX and Aln-MOF DOX
When the tumor volume of bone metastases reached at least 50 mm³, the anti-tumor therapeutic effects of MOF DOX and Aln-MOF DOX were tested in vivo. The experimental mice were divided into the following 5 groups: PBS group, Aln-MOF group, DOX group, MOF DOX group and Aln-MOF DOX group. Each group had 5 mice. The mice were treated by PBS, Aln-MOF, DOX, MOF DOX and Aln-MOF DOX through the caudal vein every 3 days for up to 4 times, respectively. The dose of DOX 5 mg/kg in group DOX, MOF DOX and Aln-MOF DOX. Group PBS was treated with equal volume of PBS as blank control, and group Aln-MOF was treated with equal dose of Aln-MOF to group Aln-MOF DOX. The mice were weighed on day 2, 4, 6, 8, 10, 12, 14, 16 and 18, and the tumor volume was calculated at the same time. The tumor volume was calculated by the following formula: tumorvolume = (length X width²)/2. The length and width of the tumor were measured at the bone metastases using vernier caliper.
On the 18th day, the mice were sacrificed and the bone metastatic tumor specimens were dissected and weighed. At the same time, tumor specimens of three typical mice were selected and photographed for recording. Sections and HE staining were performed on different tissues of the sacrificed mice, including heart, liver, spleen, lung, kidney and bone. Then different tissues were observed under a microscope for comparison.

Statistical Analyses
At least three independent tests were conducted, and the measured data were expressed as mean ± standard deviation (SD). Statistical analysis was performed by SPSS software, followed by Tukey’s test. P < 0.05 was considered statistically significant.

Results
Material Characterization
The morphological appearance of ALN-MOF and MOF were observed under TEM (Figure 1A and B). The diameters of the prepared MOF and Aln-MOF were basically around 110 nm, while the Aln-MOF size was slightly larger (Figure 1C). We detected the size changes of two nanoparticles at different time points (2, 4, 8, 24, 48, 72h), and found that the diameters did not change significantly and the stability was good (Figure 1D). Although the aggregation of nanoparticles happened, the effective size would not bigger than cells of micron level. As a result, the particle aggregation could not block blood vessels in some organs with tiny blood vessel such as liver, brain and lung.

The FTIR spectra of Aln, MOF and Aln-MOF were analyzed (Figure 2A). In the FTIR spectra of Aln, the peak at 914, 1017, 1047 cm\(^{-1}\) corresponded to stretching vibration of P-O, P-C and P=O groups, respectively. The characteristic phosphate group peak was obtained at 1545 cm\(^{-1}\), N-H stretching peaks were observed at 3482 cm\(^{-1}\). For the spectral MOF, C=N stretching peaks was observed at 1596 cm\(^{-1}\), the peak of 1046 cm\(^{-1}\) was attributed to C-N symmetric stretching, the most intense peaks at 1153 and 1114 cm\(^{-1}\) corresponded to C-N in-plane stretching, which also appeared

---

**Figure 1** Transmission electron microscopy (TEM) and dynamic light scattering tests.

**Notes:** (A) The morphology of Aln-MOF under TEM. (B) The morphology of MOF under TEM. (C) The particle diameters of MOF and Aln-MOF were about 110 nm, while Aln-MOF was slightly larger. (D) The diameters of the two particles did not change significantly at different time points (0, 2, 4, 8, 24, 48 and 72h).

**Abbreviation:** TEM, transmission electron microscopy.
in the spectrum of Aln-MOF, the peaks at 1302, 944, 756 and 680 cm\(^{-1}\) were from C-H bending in imidazole ring. The absence of characteristic phosphate peak of Aln at 1545 cm\(^{-1}\) could be considered as Aln molecules were encapsulated into MOF instead of attachment to MOF surface.

The XRD results indicated the highly crystalline formation of Aln and MOF. The XRD pattern of Aln-MOF sample was almost in agreement with MOF, and the intensity of Aln peaks was greatly reduced, suggesting that Aln molecules were efficiently encapsulated by the MOF cages, and the introduction of Aln did not cause loss of crystallinity (Figure 2B). The XPS of Aln-MOF showed a slight red shift in the N 1s binding energy, indicating that the coordination interaction between the Aln and MOF and the increased relative amount of N signal confirmed the presence of Aln in Aln-MOF (Figure 2C and D).

Drug Release Kinetics

According to the formula which mentioned above, the DOX loaded capacity of MOF and Aln-MOF particles was 0.65μg/mg. It showed that Both MOF and Aln-MOF particles could release DOX lasting for 12 hours. The release rate at pH = 5.5 was faster than that at pH = 7.4 (Figure 3). As a result, after entering bone metastatic cells from blood, Aln-MOF\(_{DOX}\) could quickly release DOX to the tumor cells due to pH changes. This pH-related characteristic was previously found in many other materials which further proved the reliability of our result.\(^{25,26}\)

Bone Affinity

When pH = 7.4 (simulated blood), the concentration of Aln-MOF was significantly reduced compared with MOF and the bone affinity of Aln-MOF was higher than MOF (P < 0.01). Similarly, when pH = 5.5 (simulating...
intracellular lysosomal enzymes), the bone affinity of Aln-MOF was also higher than that of MOF (P < 0.05) (Figure 4). No matter pH = 7.4 or pH = 5.5, Aln-MOF showed better bone affinity than MOF. The formula for calculating bone affinity: BBA(%) = (c₀ – c₁)/c₀ x 100%, where c₀ is the particle concentration of the original solution and c₁ is the particle concentration of the remaining solution after mixed with bone tissue for 24 hours. Significant differences between groups were indicated as **p < 0.01, *p < 0.05.

Abbreviation: BBA, bone-binging affinity.

Figure 4 Bone-binging affinity test.
Notes: No matter pH = 7.4 or pH = 5.5, Aln-MOF showed better bone affinity than MOF. The formula for calculating bone affinity: BBA(%) = (c₀ – c₁)/c₀ x 100%, where c₀ is the particle concentration of the original solution and c₁ is the particle concentration of the remaining solution after mixed with bone tissue for 24 hours. Significant differences between groups were indicated as **p < 0.01, *p < 0.05.

Abbreviation: BBA, bone-binging affinity.

Cytotoxicity
When the concentration of Aln-MOF increased, it had no cytotoxic effect on the 4T1 mouse cells which proved that Aln-MOF showed almost no cytotoxicity and reliable biological safety. After Aln-MOF and MOF were encapsulated with DOX, the cytotoxic effect of Aln-MOFDOX and MOFDOX on the 4T1 cells was obvious. The cytotoxic effect was enhanced by increasing the concentration (Figure 5).

Cellular Uptake
Confocal laser detection (Figure 6A and B) and flow cytometry (Figure 6C and D) were used to detect cellular uptake of Aln-MOF and MOF in the 4T1 cells. The cells could absorb Aln-MOF and MOF (Figure 6A), but it showed that the fluorescence intensities of RhoB stained Aln-MOF and MOF were similar (Figure 6B). The same result could be found in the positive cell rate and fluorescence intensity by flow cytometry (Figure 6D and E). The similar cellular uptake of Aln-MOF and MOF indicated that Aln did not influence MOF except providing bone targeting property.

Nanoparticles Distribution in vivo
Aln-MOF stayed in the blood for a longer time than MOF which was in favour of enrichment in bone metastases (Figure 7A). At 24 hours after injection, it could be seen that the concentration of Aln-MOF in the bone metastases was higher than MOF. Although MOF could enrich in the bone metastases, it would be eliminated quickly (Figure 7B). Mice were sacrificed at 24h after injection. It showed that Aln-MOF mainly concentrated at the bone metastases. However, MOF mainly concentrated in the liver, followed by bone metastases. The Aln-MOF concentration at the bone metastases was higher than MOF (P < 0.05) (Figure 8).

Anti-Tumor Effect
The tumor volumes of bone metastases at different time points were calculated, and we found that Aln-MOF had
no effect on the proliferation of bone metastases while MOFDOX and Aln-MOFDOX could significantly slow down the tumor growth compared with PBS (Figure 9A). But the effect was limited and the tumor volume initiated to increase after 12 days which are similar to previous study.27 The drug withdrawal of Aln-MOFDOX would cause recurrence of the disease, indicating that Aln-MOFDOX had useful effect but might require long-term use. The treatment plan might not be enough, and the therapeutic effect could be maximized by optimizing the frequency of administration. The body weight at different time points had no significant difference among the 5 groups (Figure 9B). Generally, drugs with high toxicity would cause weight loss. This experiment proved that our Aln-MOF and Aln-MOFDOX were biological safe. Aln-MOFDOX could significantly reduce the weight of tumor tissues and slow down tumor growth, and the therapeutic effect of Aln-MOFDOX was more obvious compared with DOX (P < 0.01) and MOFDOX (P < 0.05) (Figure 9C). The photographs of three typical tumor specimens were recorded (Figure 9D).

HE staining was performed (Figure 10) and found that Aln-MOF and Aln-MOFDOX had no obvious toxicity to other organs except for bone metastases. However, in tumor tissues, compared with other groups, the nuclei of tumor cells in group Aln-MOFDOX reduced, which indirectly indicated that Aln-MOFDOX had a killing effect on tumor cells. It could be seen that the Aln-MOFDOX had a good bone targeting property and minimize adverse reactions to other normal organs.

**Discussion**

In this study, MOF nanoparticles were selected as our DDS to deliver chemotherapy drug DOX. In order to obtain bone targeting property, we modified MOF with Aln and synthesized a new bone targeted DDS named Aln-MOF. Our study mainly proved that Aln-MOF had good bone targeting and biological safety. After DOX was encapsulated in Aln-MOF, Aln-MOFDOX could effectively kill the tumor cells of bone metastases without affecting the normal cells in other tissues. Aln-MOF could accurately deliver DOX to bone metastases and reduce the adverse reactions rate caused by DOX. MOF had been applied in the field of biomedicine, but not been used in the treatment of bone metastases in the world.

Bone metastases often cause bone metabolism imbalance especially osteolysis which will lead to SREs. Osteoblasts and osteoclasts are two important cells in bone tissue. Osteoblasts provide positive promotion for the formation of bone tissue while osteoclasts do the opposite. In normal physiological state, in order to meet the different physiological needs of the host, the microenvironment of bone tissue cells is strictly regulated. Osteoblasts and osteoclasts are in a balanced state to maintain normal bone mass.28–30 Once bone metastases occur, both osteoblast and osteoclast are activated, but the balance is closely related to the primary tumor.

In the previous studies, DDS such as nanoparticles have been used as carriers of chemotherapy drugs and widely used in the treatment of bone metastases.31–34 Among them, liposome is the most widely used DDS,
which is synthesized by lecithin and ceramide and belongs to organic DDS. Although organic DDS have good biocompatibility, the morphology and function controllability of organic DDS are poor compared with inorganic DDS. Inorganic DDS, such as SiO$_2$ particles, are easy to synthesize. They also can easily change their morphology and drug loading property according to the needs of treatment. For this reason, we chose MOF which combining inorganic and organic materials as our raw nanoparticles. Compared with traditional drug carriers such as whether organic or inorganic DDS, MOF inherited part advantages of both DDS.

No matter which DDS is to be used in vivo, the most important prerequisite is biocompatibility. Many materials, especially inorganic materials, will not be further used even if they have good drug loading and releasing property due to their biological toxicity. Our research group has demonstrated the biocompatibility and biosafety of Aln-MOF in both cells and mice through multiple experiments. In vitro, Aln-MOF was co-cultured with the 4T1 cells, and no cytotoxicity was observed. In vivo, Aln-MOF did not cause weight loss in mice and HE staining showed Aln-MOF would not damage other normal organs. It can be seen that the Aln-MOF prepared by us has good biocompatibility and biosafety which is the preconditions for further research.

Renal excretion is the main excretion route for highly polar metabolites or drugs. In addition, it is also one of the most important ways for removing the wandering external materials from body. The free materials in the blood quickly accumulate in the kidney within 1 hour after intravenous injection, and rapid excretion is performed within 4–8 hours.35–37 In our study, MOF accumulated in the kidney and was excreted quickly within 2 hours while

![Figure 6](https://www.tcpdf.org)
Aln-MOF accumulate in the kidney slowly and the renal excretion extended to 24 hours. This phenomenon might be related to the bone targeting of the material which was similar to previous studies. It can be seen that bisphosphonate has a high affinity with hydroxyapatite. Aln is the third generation of bisphosphonates, and its safety and efficacy have been clinically proven. In this study, Aln-MOF nanoparticles were synthesized by using Aln as bone targeting molecule. Because of its good bone targeting property, Aln-MOF can be used as a drug carrier for the treatment of bone metastases. In our study, although Aln-MOF had good bone targeting, it still
enriched in the liver which would affect the therapeutic effect to a certain extent. This phenomenon currently exists in many materials. At present, all targeted modification cannot avoid the removal effect of mononuclear phagocytic system (MPS) system in liver, and this is a difficult problem in the whole field of nano drug delivery. As a result, all the modifications of targeted therapy hope to improve the enrichment of the target region and improve the drug delivery effect as much as possible. The development of multiple therapeutic approaches is needed to solve liver clearance problem.

In addition, considering that most bone metastases are lytic bone metastases, Aln not only provides our nanoparticles bone targeting property but also has therapeutic effect on lytic bone destruction. Aln can play an important role in the following three aspects: 1. Aln directly acts on osteoclasts to change their morphology and promote apoptosis; 2. It binds to the bone matrix in the microenvironment of bone tissue and interferes with bone resorption. As a result, this will inhibit osteolysis. 3. It inhibits osteoblasts from releasing cytokines to repair damaged osteoclasts.40-42 It can be seen that Aln-MOF can not only be used as a carrier to deliver chemotherapy drugs but also has therapeutic effect on osteolysis related to bone metastases.

Based on the good biocompatibility, bone targeting and drug release function of Aln-MOF, it laid the foundation for us to encapsulate DOX to treat bone metastases. The killing effect of DOX on tumor cells has been confirmed by previous clinical studies. DOX is applied in a variety of malignant tumors and has broad-spectrum anti-tumor effect. DOX inhibits macromolecular protein biosynthesis by interacting with tumor cell DNA, which further inhibits the synthesis of topoisomerase II and disrupts the DNA superhelix to interfere with transcriptional function. In addition, DOX can also produce free radicals and induce DNA and cell membrane damage.43,44

Figure 9 The changes of tumor volume and weight after different treatment were detected in animal experiments.

Notes: (A) The tumor volume of bone metastatic tumor was calculated on day 0, 2, 4, 6, 8, 10, 12, 14, 16 and 18, and it was found that Aln-MOF<sub>DOX</sub> and MOF<sub>DOX</sub> could slow down the growth of bone metastases compared with PBS. (B) No significant differences were found in the weight of mice on day 0, 2, 4, 6, 8, 10, 12, 14, 16 and 18, which proved that Aln-MOF and Aln-MOF<sub>DOX</sub> were safe to body. (C) After the mice were sacrificed on day 18, the weight of tumor tissues in mice was calculated. Aln-MOF<sub>DOX</sub> could significantly reduce the weight of tumor tissues compared with DOX (p < 0.01) and MOF<sub>DOX</sub> (p < 0.05). (D) The photographs of three typical tumor specimens were recorded. Significant difference between groups was indicated as **p < 0.01, *p < 0.05.
But our study still has some limitations. First, the mechanism of Aln-MOF remains to be fully elucidated. Second, this nanoparticle shall be tested in mammal. Further studies are needed to evaluate the drug delivery property of Aln-MOF in the treatment of bone metastases.

**Conclusion**

This study confirmed that the Aln-MOF prepared by us has good stability, bone targeting and biosafety. After encapsulated with DOX, Aln-MOF<sub>DOX</sub> was able to rapidly reach higher concentrations at the bone metastases and could effectively kill tumor cells by releasing DOX. Aln-MOF<sub>DOX</sub> would not damage other normal organs. In summary, Aln-MOF is a new and effective bone targeting nano-delivery carrier, which has a very promising application prospect in the treatment of bone metastasis. We will continue to optimize the characteristics of Aln-MOF and apply it into clinical practice.

**Acknowledgments**

This study was supported by the Wenzhou Municipal Science and Technology Bureau (Grant number: Y20210400).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. *JAMA*. 2017;317(1):48–58. doi:10.1001/jama.2016.19425
2. Waning DL, Mohammad KS, Reiken S, et al. Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat Med. 2015;21(11):1262–1271. doi:10.1038/nm.3961
3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20):6243–6249. doi:10.1158/1078-0432.CCR-06-0931
4. Szade K, Gualti GS, Chan CKF, et al. Where hematopoietic stem cells live: the bone narrow niche. Antioxid Redox Signal. 2018;29(2):191–204. doi:10.1089/ars.2017.7419
5. Gdowski AS, Ranjan A, Vishwanatha JK. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res. 2017;36(1):108. doi:10.1186/s13046-017-0578-1
6. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11(6):411–425. doi:10.1038/nrc3055
7. Migliorini F, Maffulli N, Trivellas A, Eschweiler J, Tingart M, Driessen A. Bone metastases: a comprehensive review of the literature. Mol Biol Rep. 2020;47(8):6337–6345. doi:10.1007/s10053-020-05684-0
8. Lipton A. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol. 2010;37:S15–S29. doi:10.1053/j.seminoncol.2010.10.002
9. Deng X, He G, Liu J, et al. Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat Rev. 2014;40(6):730–738. doi:10.1016/j.ctrv.2014.04.003
10. Clezardin P, Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis. 2007;24(8):599–608. doi:10.1007/s10585-007-9112-8
11. Wippermann B, Mössinger E, Schratt HE, Bastian L, Krettek C. Diagnostik und Therapie von Knochenmetastasen [Diagnosis and therapy of bone metastases]. Nephrol Dial Transplant. 2007;22(3):731–736. doi:10.1093/ndt/guj062
12. Duan LN, Dang QQ, Han CY, Zhang XM. An interpenetrated bioactive nonlinear optical MOF containing a coordinated quinolone-like drug and Zn(II) for pH-responsive release. Dalton Trans. 2015;44(4):1800–1804. doi:10.1039/C4DT02672A
13. Rieter WJ, Taylor KM, An H, Lin W, Lin W. Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents. J Am Chem Soc. 2006;128(28):9024–9025. doi:10.1021/ja0627444
14. Crespo L, Sanclimens G, Pons M, Giralt E, Royo M, Albericio F. Zeolitic Imidazole Framework (ZIF) nanospheres for easy encapsulation andcontrolled release of an anticancer drug doxorubicin under different external stimuli: a way toward smart drug delivery system. Mol Pharm. 2015;12(9):3158–3166. doi:10.1021/acs.molpharmaceut.5b00043
15. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. Nanomedicine. 2020;27:102196. doi:10.1016/j.nano.2020.102196
16. Yeo JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 2005;15(1):57–62. doi:10.1038/sj.cr.7290266
17. He F, Matsumoto Y. Basic and clinical associations between bone and cancer. Immunol Med. 2020;43(3):103–106. doi:10.1080/200625785826.2020.1754084
18. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–1664. doi:10.1056/NEJMra030833
19. Markovsky E, Korukhov N, Golomb G. Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. Nanomedicine. 2007;2(4):545–553. doi:10.2217/17435889.2.4.545
20. McMenemin R, Macdonald G, Moffat L, Bissett D. A Phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulation. Invest New Drugs. 2002;20(3):331–337. doi:10.1021/adt009960b
21. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cytokidocicity. Pharmacol Res. 2004;50(2):185–229. doi:10.1124/pr.56.2.6
22. Susa M, Iyer AK, Ryu K, et al. Doxorubicin loaded polymeric nanoparticles of alendronate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer. 2009;9:399. doi:10.1186/1471-2407-9-399
23. Fazaelli Y, Akhavan O, Rahighi R, Aboudzadeh MR, Karimi E, Afsarid H. In vivo SPECT imaging of tumors by 198,199Au-labeled graphene oxide nanostructures. Mater Sci Eng C Mater Biomol Appl. 2014;45:190–204. doi:10.1016/j.msec.2014.09.019
24. Akhavan O, Ghaderi E. Graphene nanomesh promises extremely efficient in vivo photothermal therapy. Small. 2013;9(21):3593–3601. doi:10.1002/smll.201203106
25. Yang K, Zhang S, Zhang G, Sun X, Lee ST, Liu Z. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett. 2010;10(9):3318–3323. doi:10.1021/nl100996u
26. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3:S131–S139. doi:10.2215/CJN.04151206
39. Carbone EJ, Rajpura K, Allen BN, Cheng E, Ulery BD, Lo KW. Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties. *Nanomedicine*. 2017;13(1):37–47. doi:10.1016/j.nano.2016.08.015

40. Xu XL, Gou WL, Wang AY, et al. Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? *J Transl Med*. 2013;11:303. doi:10.1186/1479-5876-11-303

41. Nadar RA, Margiotta N, Iafisco M, van den Beucken JJJP, Boerman OC, Leeuwenburgh SCG. Bisphosphonate-functionalized imaging agents, anti-tumor agents and nanocarriers for treatment of bone cancer. *Adv Healthc Mater*. 2017;6(8):1601119. doi:10.1002/adhm.201601119

42. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European myeloma network. *Ann Oncol*. 2009;20(8):1303–1317. doi:10.1093/annonc/mdn796

43. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. *Mol Pharmacol*. 1994;45:649–656.

44. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. *Cancer Res*. 1976;36:2891–2895.